WO2018231078A3 - Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar - Google Patents

Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar Download PDF

Info

Publication number
WO2018231078A3
WO2018231078A3 PCT/PE2018/000014 PE2018000014W WO2018231078A3 WO 2018231078 A3 WO2018231078 A3 WO 2018231078A3 PE 2018000014 W PE2018000014 W PE 2018000014W WO 2018231078 A3 WO2018231078 A3 WO 2018231078A3
Authority
WO
WIPO (PCT)
Prior art keywords
salmonella enteritidis
strain
rough
dwaal
3934vac
Prior art date
Application number
PCT/PE2018/000014
Other languages
English (en)
French (fr)
Other versions
WO2018231078A2 (es
Inventor
Cristina LATASA OSTA
Original Assignee
Farmacologicos Veterinarios Sac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmacologicos Veterinarios Sac filed Critical Farmacologicos Veterinarios Sac
Priority to MX2019010015A priority Critical patent/MX2019010015A/es
Priority to BR112019018882A priority patent/BR112019018882A2/pt
Priority to EP18817362.9A priority patent/EP3640323A4/en
Priority to CN201880039313.4A priority patent/CN111094546A/zh
Priority to US16/491,765 priority patent/US11242521B2/en
Publication of WO2018231078A2 publication Critical patent/WO2018231078A2/es
Publication of WO2018231078A3 publication Critical patent/WO2018231078A3/es
Priority to CONC2019/0012289A priority patent/CO2019012289A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una cepa de Salmonella enteritidis 3934vac a la cual se le ha delecionado el gen waaL para obtener un fenotipo rugoso (3934vac DwaaL), el procedimiento de obtención y los oligos utilizados; con el objetivo de reducir la toxicidad y mantener la inmunogenicidad para su aplicación como vacuna. Otro aspecto de la presente invención se refiere a una cepa de Salmonella enteritidis 3934vac DwaaL, es decir de tipo rugosa, la cual ha sido modificada para expresar el gen de la fibra del adenovirus aviar tipo-I, además el procedimiento para la obtención de una cepa de Salmonella enteritidis 3034 vac DwaaL que expresa un gen de fibra de Ava-I, la invención comprende también el desarrollo de una nueva vacuna aviar, viva, recombinante, eficaz e inocua contra el virus AvA-I desarrollada vía un proceso de inserción e integración de genes de fibra Ava-I en el cromosoma de una cepa atenuada y no patogénica de la bacteria Salmonella enteritidis.
PCT/PE2018/000014 2017-06-12 2018-06-12 Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar WO2018231078A2 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2019010015A MX2019010015A (es) 2017-06-12 2018-06-12 Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar.
BR112019018882A BR112019018882A2 (pt) 2017-06-12 2018-06-12 obtenção de uma salmonela enteritidis de tipo rugosa e suas modificações genéticas para uso como vacina aviária
EP18817362.9A EP3640323A4 (en) 2017-06-12 2018-06-12 PRODUCTION OF ROUGH SALMONELLA ENTERITIDIS AND GENETIC MODIFICATIONS THEREOF FOR USE AS BIRD VACCINE
CN201880039313.4A CN111094546A (zh) 2017-06-12 2018-06-12 粗糙型肠炎沙门氏菌的获取及其用于禽流感疫苗的基因改造
US16/491,765 US11242521B2 (en) 2017-06-12 2018-06-12 Obtainment of a rough-type Salmonella enteritidis and its genetic modifications for use as an avian vaccine
CONC2019/0012289A CO2019012289A2 (es) 2017-06-12 2019-10-31 Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PE2017000992A PE20171768A1 (es) 2017-06-12 2017-06-12 Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar
PE000992-2017/DIN 2017-06-12

Publications (2)

Publication Number Publication Date
WO2018231078A2 WO2018231078A2 (es) 2018-12-20
WO2018231078A3 true WO2018231078A3 (es) 2019-03-07

Family

ID=68069984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PE2018/000014 WO2018231078A2 (es) 2017-06-12 2018-06-12 Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar

Country Status (10)

Country Link
US (1) US11242521B2 (es)
EP (1) EP3640323A4 (es)
CN (1) CN111094546A (es)
AR (1) AR112083A1 (es)
BR (1) BR112019018882A2 (es)
CL (1) CL2021000485A1 (es)
CO (1) CO2019012289A2 (es)
MX (1) MX2019010015A (es)
PE (1) PE20171768A1 (es)
WO (1) WO2018231078A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211141A1 (es) * 2019-12-19 2021-06-25 Farm Veterinarios S A C Salmonella enteritidis recombinante y su uso como vacuna porcina
PE20201405A1 (es) * 2020-09-09 2020-12-02 Farm Veterinarios S A C Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante
CN112941088B (zh) * 2021-02-04 2023-06-16 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 与布氏杆菌毒力相关的基因及其在布氏杆菌毒力评价及制备弱毒布氏杆菌中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013379A1 (es) * 2007-07-24 2009-01-29 Universidad Complutense De Madrid Cepa viva atenuada de salmonella entérica serovar choleraesuis como vacuna y vehículo vacunal para el ganado porcino
WO2009065993A1 (es) * 2007-11-21 2009-05-28 Universidad Pública de Navarra Procedimiento que permite producir modificaciones múltiples en el cromosoma de bacterias gram negativas y cepas de salmonella deficientes en síntesis de c-di-gmp obtenidas por el mismo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010108682A1 (en) * 2009-03-27 2010-09-30 Eidgenoessische Technische Hochschule Zürich Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013379A1 (es) * 2007-07-24 2009-01-29 Universidad Complutense De Madrid Cepa viva atenuada de salmonella entérica serovar choleraesuis como vacuna y vehículo vacunal para el ganado porcino
WO2009065993A1 (es) * 2007-11-21 2009-05-28 Universidad Pública de Navarra Procedimiento que permite producir modificaciones múltiples en el cromosoma de bacterias gram negativas y cepas de salmonella deficientes en síntesis de c-di-gmp obtenidas por el mismo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KONG Q. ET AL.: "Effect of Deletion of Genes Involved in Lipopolysaccharide Core and O-Antigen Synthesis on Virulence and Immunogenicity of Salmonella enterica Serovar Typhimurium", INFECTION AND IMMUNITY, vol. 79, no. 10, 2011, pages 4227 - 4239, XP009155080 *
LATASA C. ET AL.: "Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine", PLOS ONE, 2016, pages 1 - 22, XP055579773 *

Also Published As

Publication number Publication date
PE20171768A1 (es) 2017-12-21
BR112019018882A2 (pt) 2020-04-14
CL2021000485A1 (es) 2021-07-02
EP3640323A2 (en) 2020-04-22
MX2019010015A (es) 2019-11-21
US11242521B2 (en) 2022-02-08
AR112083A1 (es) 2019-09-18
EP3640323A4 (en) 2021-03-17
CN111094546A (zh) 2020-05-01
WO2018231078A2 (es) 2018-12-20
CO2019012289A2 (es) 2020-01-17
US20200370034A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
WO2018231078A3 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
Gohrbandt et al. H9 avian influenza reassortant with engineered polybasic cleavage site displays a highly pathogenic phenotype in chicken
CY1121528T1 (el) Ανασυνδυασμενοι φορεις ερπητοϊου gallid 3 (mdv οροτυπου 2) που εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
WO2021155243A8 (en) Respiratory virus immunizing compositions
MX2016016722A (es) Coronavirus.
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
Rockx-Brouwer et al. Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination
WO2010033798A3 (en) Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
MD4481C1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
PE20151080A1 (es) Cepas de streptomyces microflavus y metodos de uso de las mismas para controlar enfermedades y plagas en plantas
EA201692468A1 (ru) Аттенуация вируса путем холодовой адаптации (cava) и новые аттенуированные штаммы полиовируса
MX366836B (es) Celulas aviares para la produccion mejorada de virus.
BR112017005441A2 (pt) método para transformar uma célula de planta ou tecido de planta usando agrobacterium, planta transgênica, célula transgênica ou tecido transgênico, meio de cultura, e, uso de um método.
MX2020006869A (es) Plantas con genes dhs modificados.
MX2018000353A (es) Sistema vector de adenovirus aviar 9 (fadv-9) y metodos asociados.
Kunec et al. Synthetically recoded virus sCPD9–A tool to accelerate SARS-CoV-2 research under biosafety level 2 conditions
PH12020500526A1 (en) Paramyxoviridae expression system
WO2023218388A3 (en) Process for the production of irisin, its formulations and its administration routes
MX2020007676A (es) Antígenos t grandes y pequeños del poliomavirus de células de merkel, construcciones de ácido nucleico y vacunas fabricadas con ellos, y métodos de usar los mismos.
WO2018236086A3 (ko) 신규한 에로모나스 하이드로필라 박테리오파지 Aer-HYP-2 및 이의 에로모나스 하이드로필라 균 증식 억제 용도
WO2004064776A3 (en) Methods of preparation of live attenuated bacterial vaccines by alteration of dna adenine methylase (dam) activity in those bacteria
MX2022007508A (es) Salmonella enteritidis recombinante y su uso como vacuna porcina.
CL2019003108A1 (es) Obtención de una salmonela enteritidis tipo rugosa y sus modificaciones genéticas para uso como vacuna aviar.
Soares et al. Study of the viability of Aspergillus strains freeze-dried in 1955

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18817362

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019018882

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018817362

Country of ref document: EP

Effective date: 20200113

ENP Entry into the national phase

Ref document number: 112019018882

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190911